ELOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Eloxx Pharmaceuticals's enterprise value is $3.81 Mil. Eloxx Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Eloxx Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for Eloxx Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Eloxx Pharmaceuticals was 629.36. The lowest was -7.08. And the median was 76.73.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-20), Eloxx Pharmaceuticals's stock price is $0.85. Eloxx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Eloxx Pharmaceuticals's PS Ratio for today is .
The historical data trend for Eloxx Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eloxx Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Eloxx Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EV-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Eloxx Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Eloxx Pharmaceuticals's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Eloxx Pharmaceuticals's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 3.812 | / | 0 | |
= |
Eloxx Pharmaceuticals's current Enterprise Value is $3.81 Mil.
Eloxx Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eloxx Pharmaceuticals (OTCPK:ELOX) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Eloxx Pharmaceuticals's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.85 | / | 0 | |
= |
Eloxx Pharmaceuticals's share price for today is $0.85.
Eloxx Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumit Aggarwal | director, officer: PRESIDENT AND CEO | 480 ARSENAL WAY, WATERTOWN MA 02472 |
Vijay Modur | officer: HEAD OF R&D | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451 |
Lindsay Androski | director | C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Gadi Veinrib | director | 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101 |
Steven D Rubin | director | OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Jasbir Seehra | director | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Zafrira Avnur | director | 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467 |
Alan Edmund Walts | director | 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129 |
Daniel E. Geffken | officer: Chief Financial Officer | DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742 |
Pontifax Iv Gp L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (israel) Iv, L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (china) Iv L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (cayman) Iv L.p. | 10 percent owner | 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Ran Nussbaum | director | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
From GuruFocus
By sperokesalga sperokesalga • 05-24-2023
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-15-2022
By Marketwired • 10-09-2023
By Value_Insider Value_Insider • 11-01-2022
By Marketwired • 08-03-2023
By Marketwired • 06-21-2023
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 09-19-2023
By sperokesalga sperokesalga • 03-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.